Covas Dimas Tadeu, de Lucena Angulo Ivan, Vianna Bonini Palma Patricia, Zago Marco Antonio
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Centro de Terapia Celular, CEPID, FAPESP, Ribeirão Preto, SP, Brazil.
Haematologica. 2004 Mar;89(3):273-80.
Adhesion molecules on the surface of erythrocytes, leukocytes and platelets are involved in vascular occlusion in sickle cell anemia. Hydroxyurea treatment of sickle cell anemia patients leads to clinical improvement and reduces the incidence of vaso-occlusive episodes. It has been previously demonstrated that hydroxyurea treatment also reduces the expression of adhesion molecules on the surface of erythrocytes. Phosphatidylserine (PS) exposure on the surface of erythrocytes has been considered to be the main determinant of altered erythrocyte adhesion in sickle cell anemia. In this study we examine the expression of PS on the surface of erythrocytes and platelets of sickle cell anemia patients before and during treatment with hydroxyurea.
Blood samples from 15 sickle cell anemia patients were analyzed before and during treatment with hydroxyurea. The profile of PS expression was examined by flow cytometry.
Hydroxyurea was effective, as determined by the patients clinical improvement and increased hemoglobin (8.3 vs 9.1 g/dL, p< 0.005), F cells (15.9% vs 37.1%, p< 0.005) and mean corpuscular volume ( 82 fL vs 101 fL, p< 0.005). PS expression on the surface of erythrocytes and platelets decreased from 6.27% to 2.96% (p< 0.005) and from 13.5% to 4.7% (p< 0.005), respectively.
Hydroxyurea treatment reduces PS expression on the surface of erythrocytes and platelets, thus contributing to the favorable effects of this therapy.
红细胞、白细胞和血小板表面的黏附分子参与镰状细胞贫血的血管闭塞过程。羟基脲治疗镰状细胞贫血患者可带来临床改善并降低血管闭塞性发作的发生率。此前已证明,羟基脲治疗还可降低红细胞表面黏附分子的表达。红细胞表面磷脂酰丝氨酸(PS)暴露被认为是镰状细胞贫血中红细胞黏附改变的主要决定因素。在本研究中,我们检测了镰状细胞贫血患者在羟基脲治疗前及治疗期间红细胞和血小板表面PS的表达情况。
对15例镰状细胞贫血患者在羟基脲治疗前及治疗期间采集的血样进行分析。通过流式细胞术检测PS表达情况。
羟基脲治疗有效,这可通过患者的临床改善情况以及血红蛋白升高(8.3 vs 9.1 g/dL,p<0.005)、F细胞增多(15.9% vs 37.1%,p<0.005)和平均红细胞体积增大(82 fL vs 101 fL,p<0.005)得以确定。红细胞和血小板表面的PS表达分别从6.27%降至2.96%(p<0.005)和从13.5%降至4.7%(p<0.005)。
羟基脲治疗可降低红细胞和血小板表面的PS表达,从而有助于该疗法产生良好效果。